Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

NCT02002884 is registered in ClinicalTrials.gov with Merz Pharmaceuticals GmbH as lead sponsor.

NCT NCT02002884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02002884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Lead sponsor
Merz Pharmaceuticals GmbH
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2014
Completion date
August 28, 2018
Enrollment
351 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral palsy, spasticity